Publications by authors named "Peter Buggisch"

Claim this Profile
I
Impact of Handling Perception and Language Barriers on Virologic Response to Daily Subcutaneous Bulevirtide in Hepatitis D.
Toni Herta, Christopher Dietz-Fricke, Münevver Demir, Kathrin Sprinzl, Kai-Henrik Pfeiffer, Peter Buggisch

Liver Int· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment gaps and survival outcomes of hepatocellular carcinoma: insights from a nationwide, claims-based study.
Simone Schrodi, Karin Berger-Thürmel, Selina Becht, Michael von Bergwelt-Baildon, Peter Buggisch

Ther Adv Med Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating Resmetirom Eligibility Among Patients with MASH: Insights from the German Steatotic Liver Disease-Registry.
Eva Katharina Messer, David Petroff, Jörn Schattenberg, Stefan Zeuzem, Manfred von der Ohe, Peter Buggisch

Z Gastroenterol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic Dysfunction-Associated Steatohepatitis Diagnosis and Management in Germany: Insights From an Expert Consensus Panel.
Yestle Kim, Peter Rydqvist, Thomas Ramezani, Jennifer S Haas, Heike Bantel, Peter Buggisch

Liver Int· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results.
Cynthia Levy, Palak J Trivedi, Kris V Kowdley, Stuart C Gordon, Christopher L Bowlus, Peter Buggisch

Am J Gastroenterol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of distinct antiviral treatment regimens on the long-term outcome after HCV cure - Data from the German Hepatitis C-Registry (DHC-R).
Valerie Ohlendorf, Yvonne Serfert, Peter Buggisch, Stefan Mauss, Hartwig Klinker

Z Gastroenterol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Treatment strategies for hepatitis B, C and D].
Jörg Petersen, Peter Buggisch

MMW Fortschr Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recompensation of Liver Cirrhosis by TIPS Reduces Epithelial Cell Death Markers, Translating Into Improved Clinical Outcome.
Felix Piecha, Beatrice-Victoria Jahn, Johannes Köntopf, Anja Koop, Ann-Kathrin Ozga, Peter Buggisch

Liver Int· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
ReLink strategy in diagnosed-but-untreated hepatitis C-positive patients in Germany: report from a single center.
Sarah Lange, Christina Baehr, Nur Irem Cakman-Hinrichs, Katharina Cron, Hannah Fengels, Peter Buggisch

Z Gastroenterol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients.
Julia Dietz, Christiana Graf, Christoph P Berg, Kerstin Port, Katja Deterding, Peter Buggisch

JHEP Rep· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
Gideon M Hirschfield, Christopher L Bowlus, Marlyn J Mayo, Andreas E Kremer, John M Vierling, Peter Buggisch

N Engl J Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R).
Kathrin Krüger, Siegbert Rossol, Christian Krauth, Peter Buggisch, Stefan Mauss

Z Gastroenterol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.
Florian van Bömmel, Kerstin Stein, Renate Heyne, Jörg Petersen, Peter Buggisch

J Hepatol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treating hepatitis D with bulevirtide - Real-world experience from 114 patients.
Christopher Dietz-Fricke, Frank Tacke, Caroline Zöllner, Münevver Demir, Hartmut H Schmidt, Peter Buggisch

JHEP Rep· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
Julia Dietz, Beat Müllhaupt, Peter Buggisch, Christiana Graf, Kai-Henrik Peiffer

J Hepatol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany - First data from the German NAFLD-Registry.
Andreas Geier, Monika Rau, Anita Pathil-Warth, Manfred von der Ohe, Jörn Schattenberg, Peter Buggisch

Z Gastroenterol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry.
Frank Tacke, Hartwig Klinker, Klaus H W Boeker, Uta Merle, Ralph Link, Peter Buggisch

Hepatol Commun· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of steatosis in the clinical course of chronic HCV infection-Results from the German Hepatitis C-Registry.
Monika Rau, Peter Buggisch, Stefan Mauss, Klaus H W Boeker, Hartwig Klinker

PLoS One· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study.
Peter Buggisch, Hans Heiken, Stefan Mauss, Bernd Weber, Maria-Christina Jung

PLoS One· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R).
Dietrich Hüppe, Albrecht Stoehr, Peter Buggisch, Stefan Mauss, Hartwig Klinker

J Viral Hepat· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of recurrent hepatic encephalopathy in patients with liver cirrhosis: a German registry study.
Maria M Gabriel, Gerald Kircheis, Svenja Hardtke, Daniel Markwardt, Peter Buggisch

Eur J Gastroenterol Hepatol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of gender on cytokine induced depression and treatment: Gender aspects of IFN-α-induced depression.
Susanne Sarkar, Jonas Kemper, Rahul Sarkar, Loni Brants, Astrid Friebe, Peter Buggisch

J Affect Disord· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease.
Wan-Long Chuang, Tsung-Hui Hu, Peter Buggisch, Christophe Moreno, Wei-Wen Su

Am J Gastroenterol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Evolution of hepatitis C virus genotype 1a vs. 1b distribution in Germany between 2004 and 2018 - An analysis of 17093 patients from different real world registries].
Karl-Georg Simon, Yvonne Serfert, Peter Buggisch, Stefan Mauss, Klaus H W Boeker

Z Gastroenterol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care.
Wolf Peter Hofmann, Peter Buggisch, Lisa Schubert, Nektarios Dikopoulos, Jeannette Schwenzer

JHEP Rep· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis